Compensatory activation of estrogen receptor α signaling in acquired resistance to lapatinib of HER2-overexpressing/ERα-positive breast cancer cells

Academic Journal of Second Military Medical University

Volumn 34, Issue 6, 2013, Pages 616-622

  Li, Zhe ^a   Chang, Tao ^a   Shi, Lin Xiang ^a   Fang, Lin ^a   Yang, Sheng Sheng ^b   Fang, Guo En ^c  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasms; erbB 2 receptor; Estrogen receptor alpha; Lapatinib; Neoplasm drug resistance

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; COLONY FORMATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84922686529     PISSN: 0258879X     EISSN: None     Source Type: Journal    
DOI: 10.3724/Sp.J.1008.2013.00616     Document Type: Article

References (24)

1. Pommier S J, Quan G G, Christante D, Muller P, Newell A E, Olson SB, et al. Characterizing the HER2/neu status and metastatic potential of breast cancerstem/ progenitor cells [J], Ann Surg 0ncol, 2010,17 613-623.
2. Jemal A, Siegel R, Xu J, Ward E. Cáncer statistics,2010 [J]. CA Cáncer J Clin,2010, 60: 277-300.
3. Wang Y C, Morrison G, Gillihan R, Guo J, Ward R M, Fu X, et al. Different mechanisms for resistance to tras-tuzumab versus lapatinib in HER2-positive breast canc-ers-role of estrogen receptor and HER2 reactivation [J], Breast Cáncer Research,2011, 13:R121.
4. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A modil of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strat-egy to prevent its onset in breast cancer[J], Proc Natl Acad Scf USA,2006,103:7795-7800.
5. Bender L M, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer[J], FrontBiosci, 2008, 13: 3906-3912.
6. Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Mur-ray N, Loftiss J, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in pa-tients with advanced cancer[J], Clin Cáncer Res,2008, 14:4484-4490.
7. Bauerfeind I, Elling D, Heinemann V. Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast cancer[J], Breast Care (Basel),2010,5(s1);13-15.
8. Geyer C E, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cáncer [J]. N Engl J Med,2006,355: 2733-2743.
9. Macfarlane R J, Gelmon K A. Lapatinib for breast cáncer: a review of the current literature[J]. Expert 0pin Drug Saf,2011,10:109-121.
10. Esteva F J, Yu D, Hung M C, Hortobagyi G N. Molecular predictors of response to trastuzumab and lapatinib in breast cáncer [J]. Nat Rev Clin 0ncol, 2010, 7: 98-107.
11. Gómez H L, Do val D C, Chavez M A, Ang P C, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advancedor metastatic breast cáncer[J], J Clin 0ncol,2008,26:2999-3005
12. Eichhorn P J, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyper-activation results in lapatinib resistance that is reversed by the mT0R/phosphatidylinositol3-kinase inhibitor NVP-BEZ235[J], Cáncer Res,2008,68:9221-9230.
13. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer[J], Proc Natl Acad Sci USA,2008,105:12463-12468.
14. Sergina N V, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 [J], Nature,2007,445:437-441.
15. Campone M, Juin P, André F, Bachelot T. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimen-tation[J], Crit Rev 0ncol Hematol,2011,78:195-205.
16. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novll mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL [J]. Cáncer Res,2009,69:6871-6878.
17. Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FG-FR2 as a potential target for salvage after lapatinib faü-ure[J], Biochem Biophys Res Commun, 2011, 407: 219-224.
18. Rexer B N, Ham A J, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo A M, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition[J], 0nco-gene,2011,30;4163-4174.
19. Guo S, Sonenshein G E. Forkhead box transcription factor F0X03aregulates estrogen receptor alpha ex-pression and is repressed by the Her-2/neu/phosphati-dylinositol 3-kinase/Akt signaling pathway [J]. Mol Cell Biol,2004,24: 8681-8690.
20. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the P--3K and MEK pathways in Ras-mediated chemoresis-tance in breast cáncer cells[J], British J Cáncer, 2003, 89:185-191.
21. Atanaskova N, Keshamouni V G, Krueger J S, Schwartz J A, Miller F, Reddy K B. MAP kinase/ estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance [J]. 0ncogene,2002,21: 4000-4008.
22. Zora N, Dragica N. Cross-talk between ER and HER2 in breast carcinoma[J]. Archive 0ncol, 2006, 14: 146-150.
23. Edwards D P. Regulation of signal transduction pathways by estrogen and progesterone[J], Ann Rev Phyii-ol,2005, 67: 335-376.
24. Lange C A, Gioeli D, Hammes S R, Marker P C. Inte-gration of rapid signaling events with steroid hormone receptor action in breast and prostate cáncer[J]. Ann Rev Physiol,2007,69:171-199.